ClinicalTrials.gg
RecruitingNCT04633252Updated Oct 29, 2026

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

A Phase 1/2 interventional study of PDS01ADC and Docetaxel in Cancer Of Prostate and Prostate Neoplasms, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to male participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years to 110 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Planned enrollment
50th of 185
86 · median 39
Started
2021
with 4 others
Phase 1/2
23 of 193
3 open now
Primary completion
2026-12
later than 8 of 23 live
Registered
173rd of 193
by date
Lead sponsor
8 of 193
National Cancer Institute (NCI)

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 50th largest by planned enrollment of the 185 interventional ones that give a count, is one of 5 that started in 2021, is one of 23 in phase 1/2, reaches primary completion later than 8 of the 23 other live ones, and was the 173rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 110 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Background:

Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivation therapy can improve survival for men with mCSPC. Researchers want to see if combining this treatment with other drugs can help delay the time it takes for mCSPC and mCRPC to get worse.

Objective:

To learn if giving docetaxel with PDS01ADC is safe and effective for men with prostate cancer.

Eligibility:

Men age 18 and older with mCSPC or mCRPC.

Design:

Participants will be screened with a medical history and physical exam. Their diagnosis will be confirmed. Their symptoms and how well they do their normal activities will be reviewed. They will have blood and urine tests. Their heart will be evaluated. They will have imaging scans of the chest, abdomen, and pelvis. They will have bone scans with intravenous (IV) injections of Tc99 to check for tumor spread in the bones.

Some screening tests will be repeated during the study.

Participants may have tumor biopsies.

Participants will get treatment in cycles. Each cycle will last 21 days. They will get docetaxel through IV infusion. They will get PDS01ADC as an injection under the skin.

Participants with mCSPC will have up to 6 cycles. Those with mCRPC will be treated until they cannot tolerate the side effects or their disease gets worse.

Participants will have a follow-up visit 30 days after treatment ends. Those with mCSPC will then have follow-up visits at the clinic every 3 months.

Read the detailed description

Background:

  • A phase III trial demonstrated that combining docetaxel and androgen deprivation therapy (ADT) significantly improved survival (57.6 vs 44.0 months (hazard ratio HR=0.56, (0.44- 0.70), p \<0.0001) for men with metastatic castration sensitive prostate cancer (mCSPC). The greatest benefit was seen in men with high volume disease (visceral disease or 4+ bone lesions with at least one beyond the pelvis and spine.)
  • Docetaxel has limited efficacy in metastatic castration resistant prostate cancer (mCRPC) patients who have already progressed on anti-androgen therapy (abiraterone or enzalutamide).
  • Intensification of treatment in de novo mCSPC patients by adding abiraterone to docetaxel and ADT has been shown in a phase III trial to significantly improve OS (0.82, (0.69 - 0.98) p=0 (Summation)030) and rPFS (HR=0.54,(0.41-0.71) p \<0.0001)
  • Clinical data have indicated that PSA \<=0.20 ng/ml eight months after starting androgen deprivation therapy (ADT) is prognostic for overall survival based on data from the phase III trial.
  • Preclinical data demonstrates that docetaxel increases uptake of PDS01ADC, an IL-12 immunocytokine that targets necrosis.
  • Additional preclinical data demonstrates the potential anti-tumor synergy of PDS01ADC when combined with docetaxel.

Objectives:

Phase I:

To evaluate safety and tolerability of docetaxel in combination with PDS01ADC in participants who have metastatic prostate cancer.

Phase II:

-Determine clinical efficacy in adults with prostate cancer treated when standard of care is combined with PDS01ADC. For mCSPC the standard of care is docetaxel + abiraterone. For mCRPC the standard of care is docetaxel.

  • For mCSPC participants: Clinical efficacy will be measured by prostate specific antigen (PSA \<0.2 ng/ml) eight months after start of androgen deprivation therapy (ADT).
  • For mCRPC participants: Clinical efficacy will be measured by an increase in their median progression free survival (PFS).

Eligibility:

  • Men age >=18 years
  • Histopathological confirmation of prostate cancer. If no pathologic specimen is available, participants may enroll with a pathologist s report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease.
  • Participants must have metastatic disease

    • mCSPC participants must be within 134 days of starting ADT.
    • mCRPC participants must have been previously treated with ADT.

Design:

  • Open-label, single-center, non-randomized Phase I/II study
  • To ensure safety of the combination before using in larger numbers of mCSPC and mCRPC participants, PDS01ADC will be escalated from a starting dose of 12 mcg/kg and a second dose level of 16.8 mcg/kg along with docetaxel. mCSPC participants will receive a maximum of 6 cycles. mCRPC participants will continue until progression or unacceptable toxicity.
  • The remaining participants will be enrolled onto the trial in the following expansion cohorts, each of which will receive the determined safe dose of PDS01ADC. ADT will be maintained/given per standard of care throughout the study.

    • mCSPC participants: Once ADT established, simultaneous docetaxel 75 mg/m\^2 (given every 3 weeks x 6 cycles starting at Cycle 1), with PDS01ADC at the RP2D, given every 3 weeks from cycle 2 through cycle 6). Abiraterone will be given in addition to docetaxel from the start of cycle 1 at a dose of 1000mg by mouth once daily. Prednisone will be given orally at 5 mg twice a day and will not be optional.
    • The first 6 participants in the mCSPC arm including abiraterone will be evaluated as a safety lead-in of PDS01ADC at 12 mcg/kg. If there are 2 or more DLTs within these initial 6, then the doses will be de-escalated and 6 additional participants will be evaluated at this lower dose of PDS01ADC at 8 mcg/kg.
    • mCRPC participants: docetaxel 75 mg/m\^2 (given every 3 weeks starting at Cycle 1) with PDS01ADC at the RP2D, given every 3 weeks from cycle 2 onwards until disease progression or unacceptable toxicity. Prednisone will be given 5 mg twice a day for each dose or 10 mg once a day.
  • It is anticipated that approximately 4 years may be required for accrual of up to 80 participants.
03

Conditions studied

  • Cancer Of Prostate
  • Prostate Neoplasms

Browse trials for

Keywords

  • Chemoimmunotherapy
  • NHS IL-12
  • Check point inhibitor
  • Combination Therapy
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have documented histopathological confirmation of prostate cancer. If no pathologic specimen is available, participants may enroll with a pathologist's report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease.
  • Participants must have disease, defined as at least one lesion on TC99 bone scan or at least one lesion that is measurable per, per 1.1.
  • mCSPC participants:
  • Participants must be within 134 days of starting ADT.
  • If participants are on ADT and responding, this may impact the findings on scans. Pre- treatment scans could be used to confirm that participants have metastatic high-volume disease in such cases.

    • For Cohorts 1 and 2, Dose escalation and Safety Run-in, only: mCSPC may have high or low volume disease.
    • For Cohort 3, Dose Expansion: mCSPC participants must have high volume disease (as defined by visceral lesion or 4 or greater bone lesions, at least one of which is beyond the spine and pelvis).
  • mCRPC participants:
  • Must need ADT as part of their cancer therapy (unless previous orchiectomy)
  • Must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide.
  • Must have not had progression while on docetaxel if given for mCSPC or within 3 months of completing docetaxel for mCSPC.
  • Progression defined as either rising PSA greater than 2.0 ng/ml or radiographic evidence of progression seen on CT scan or TC-99 bone scan.
  • Toxicities related to prior therapy, including surgery and/ or radiation, must have resolved to \<= grade 1.
  • Men age >=18 years. Because no dosing or adverse event data are currently available on the use ofINCLUSION CRITERIA:
  • Participants must have documented histopathological confirmation of prostate cancer. If no pathologic specimen is available, participants may enroll with a pathologist's report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease.
  • Participants must have metastatic disease, defined as at least one lesion on TC99 bone scan or at least one lesion that is measurable per, per RECIST 1.1.
  • mCSPC participants:
  • Participants must be within 134 days of starting ADT.
  • If participants are on ADT and responding, this may impact the findings on scans. Pre- treatment scans could be used to confirm that participants have metastatic high-volume disease in such cases.

    • For Cohorts 1 and 2, Dose escalation and Safety Run-in, only: mCSPC may have high or low volume disease.
    • For Cohort 3, Dose Expansion: mCSPC participants must have high volume disease (as defined by visceral lesion or 4 or greater bone lesions, at least one of which is beyond the spine and pelvis).
  • mCRPC participants:
  • Must need ADT as part of their cancer therapy (unless previous orchiectomy)
  • Must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide.
  • Must have not had progression while on docetaxel if given for mCSPC or within 3 months of completing docetaxel for mCSPC.
  • Progression defined as either rising PSA greater than 2.0 ng/ml or radiographic evidence of progression seen on CT scan or TC-99 bone scan.
  • Toxicities related to prior therapy, including surgery and/ or radiation, must have resolved to \<= grade 1.
  • Men age >=18 years. Because no dosing or adverse event data are currently available on the use of PDS01ADC in combination with docetaxel in participants \<18 years of age, children are excluded from this study.
  • performance status 0-2.
  • Participants must have adequate organ and marrow function as defined below:
  • >=1,500/mcL, without CSF support
  • >=100,000/mcL
  • >9 g/dL
  • PT \<= 1.5 x
  • \<= 1.5 x ULN
  • Total \<= upper limit of normal (ULN), OR in participants with Gilbert's syndrome, a total bilirubin \<= 3.0
  • Serum albumin >=2.8 g/dL
  • (SGOT)/ALT(SGPT) \<=1.5 X institutional upper limit of normal

    -- Hepatic function based on Class: Participants with hepatic impairment must have Child-Pugh Class A or better

  • Serum Creatinine OR \<= 1.5 X institutional upper limits of normal OR >=50 mL/min/1.73 m\^2 calculated by in the clinical lab for participants with serum creatinine levels > 1.5 ULN
  • The effects of PDS01ADC in combination with docetaxel and abiraterone on the developing human fetus are unknown. For this reason and because docetaxel agents as well as other immuno-therapeutic agents used in this trial are known to be teratogenic, sexually active subjects and their female partners must agree to use medically accepted barrier methods of (e.g., male or female condom)after enrollment on study , during the study treatment and for 4 months after the last dose of abiraterone, docetaxel or PDS01ADC, even if oral contraceptives are also used. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately and her partner should inform the study doctor immediately.
  • Ability of subject to understand and the willingness to sign a written document. Subject should be willing to travel to the NIH for follow-up visits.
  • Participants with prior immune checkpoint therapy are eligible to enroll upon PI discretion.

Exclusion criteria

EXCLUSION CRITERIA:

  • status due to:

    • (HIV) positivity
    • Active diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave's disease. Participants with a history of autoimmunity that has not required systemic immunosuppressive therapy or does not threaten vital organ function including CNS, heart, lungs, kidneys, skin, and GI tract will be allowed.
    • Other immunodeficiency diseases that in the opinion of the investigator could compromise the participant or limit treatment efficacy
  • Serious intercurrent medical illness that, in the judgment of the investigator, would interfere with participant s ability to carry out the treatment program.
  • Current use of other medications for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g. phytoestrogens and saw palmetto).
  • Concurrent use of inducers or sensitive CYP2D6 substrates within 14 days or 5 half-lives, whichever is shorter.
  • Receipt of any agent within 28 days (or 60 days for an antibody drug conjugates) before the first planned dose of study drugs.
  • Participants who are positive for surface antigen and/or Anti- antibody
  • Uncontrolled hypertension (SBP>170/ DBP>105)
  • Has received or will receive a within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus are permitted. Locally approved COVID vaccines are permitted.
  • Participants who have had prior docetaxel for mCRPC
  • mCSPC participants will be excluded if they did not start abiraterone within 6 weeks of ADT and/or had any docetaxel
  • Participants who have had progression within 3 months of completing docetaxel for mCSPC
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to PDS01ADC investigational agents used in the study
  • The subject has had evidence within 3 years of the start of study treatment of another active which required systemic treatment (except for nonmelanoma skin cancers or carcinoma in situ of the bladder).
  • The subject has active or epidural disease.
  • Participants with greater than or equal to grade 2 peripheral neuropathy (defined by 5.0) at baseline.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    1/Dose Escalation

    Docetaxel plus PDS01ADC dose escalation with optional prednisone and ADT as part of SOC

    Drug: PDS01ADC · Drug: Docetaxel · Drug: Prednisone · Drug: ADT

  • Experimental
    2/Safety Run-in (no longer applies; removed before enrollment)

    Docetaxel plus PDS01ADC RP2D plus M7824 with optional prednisone and ADT as part of SOC

    Drug: PDS01ADC · Drug: Docetaxel · Drug: M7824 · Drug: Prednisone · Drug: ADT

  • Experimental
    3/mCSPC: Dose Expansion

    Docetaxel plus PDS01ADC RP2D with optional prednisone and ADT as part of SOC

    Drug: PDS01ADC · Drug: Docetaxel · Drug: Prednisone · Drug: ADT

  • Experimental
    4/mCRPC: Dose Expansion

    Docetaxel plus PDS01ADC RP2D with optional prednisone and ADT as part of SOC

    Drug: PDS01ADC · Drug: Docetaxel · Drug: Prednisone · Drug: ADT

Interventions

  • DrugImmunocytokine NHS-IL12Studies of Immunocytokine NHS-IL12Immunocytokine NHS-IL12 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PDS01ADC at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.

  • Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.

  • DrugBintrafusp alfaStudies of Bintrafusp alfaBintrafusp alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.

  • For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.

  • DrugAntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.

06

What researchers measure

Primary outcomes

  1. Determine clinical efficacy in adults with prostate cancer treated with docetaxel in combination with the immunocytokine, PDS01ADC

    For castration sensitive: Increase in the proportion of participants who have less than 0.2 ng/ml of PSA. For castration resistant: Increase in median progression free survival

    Time frame: 4-8 weeks

  2. To evaluate safety and tolerability of docetaxel in combination with PDS01ADC in patients who have metastatic prostate cancer.

    of the number and type of toxicities noted for participants who are evaluable for toxicity

    Time frame: DLT observation period (until the end of 6 weeks)

Secondary outcomes

  1. Evaluate radiographic response rates

    Tumor progression on scans

    Time frame: 4-8 weeks

  2. Evaluate percentage of patients with a 50% PSA decline from baseline

    PSA levels

    Time frame: 4-8 weeks

  3. Evaluate radiographic and biochemical time to progression for mCSPC patients

    PSA levels and tumor progression on scans

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office · Contact888-624-1937
08

References and documents

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGAP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as the database is active.

Access criteria: Clinical data will be made available via subscription to BTRIS and with permission of the study PI. Genomic data are made available via dbGAP through requests to the data custodians.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 70 months is close to that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2020
First posted
Nov 18, 2020
StartActual
Feb 23, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
3 updates, last Oct 29, 2026
Show all 3 updates
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04633252
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Feb 23, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Amy R Hankin, P.A.-C
Contact
amy.hankin@nih.gov
(240) 858-3149
Melissa L Abel, M.D.
Contact
melissa.abel@nih.gov
(240) 447-5353
Melissa L Abel, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunocytokine NHS-IL12 · Docetaxel

Start the discussion